News | July 09, 2025
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
The company showcased three core programs developed through this platform
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
Subscribe To Our Newsletter & Stay Updated
